drugset
drugset / Trial / NCT04425824

Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

NCT04425824 ↗

Phase 2 Unknown 20 enrolled Chinese Academy of Medical Sciences
NaSingle-groupOpen-labelTreatment

Summary

Exploring the efficacy and safety of Toripalimab with Rituximab for treatment of relapsed refractory CD20 positive diffuse large B-cell lymphoma.

Timeline

Start
2020-06-15
Primary completion
2022-12-31
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Subject Toripalimab Monoclonal antibody 240 mg Intravenous

Indications

diffuse large B-cell lymphoma